# OnCo record daunorubicin (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/daunorubicin/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "daunorubicin" ;
  schema:name "Daunorubicin"@en ;
  schema:alternateName "Daunomycin"@en, "Rubidomycin"@en, "Cerubidine (historic)" ;
  schema:description "Daunorubicin is the anthracycline most often combined with cytarabine to bring acute myeloid leukaemia into remission; it is also part of induction for acute lymphoblastic leukaemia."@en ;
  schema:url <https://onco.cc/drugs/daunorubicin/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Daunorubicin> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=daunorubicin>, <https://www.cancer.gov/about-cancer/treatment/drugs/daunorubicinhydrochloride> ;
  onco:status "approved" ;
  onco:tag "nci-list", "generic" ;
  onco:modality "Anthracycline (topoisomerase II inhibitor)" ;
  onco:approval "US 1979: Remission induction in acute non-lymphocytic leukaemia (adults) and acute lymphocytic leukaemia (adults and children), in combination" ;
  onco:related <https://onco.cc/drugs/cytarabine-7-3/>, <https://onco.cc/drugs/cpx-351/>, <https://onco.cc/drugs/doxorubicin/> ;
  onco:cancers <https://onco.cc/cancers/aml/>, <https://onco.cc/cancers/all-leukemia/> ;
  onco:technologies <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/topoisomerase-inhibitors/> ;
  onco:trials <https://onco.cc/trials/nct07007312/>, <https://onco.cc/trials/nct03591510/>, <https://onco.cc/trials/nct07255872/> .